US › Healthcare

Contineum Therapeutics, Inc. Class A Common Stock (CTNM)

US · Healthcare · Biotechnology

$15.90-0.19%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-15.2M
Profit YoY
+5.5%
EPS
$-0.40
EPS estimate
$-0.46

EPS came in at -0.40 against a street estimate of -0.46 — a beat of 13.0%.

Key statistics

Market cap
$582.8M
Forward P/E
0.0
P/B
2.43
Book value
$6.37
EPS (TTM)
$-1.72
52-week high
$16.91
52-week low
$5.71
50-day MA
$13.66
200-day MA
$12.90
Beta
0.70

Analyst view

Analysts rate Contineum Therapeutics, Inc. Class A Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $22.86.

Shareholding

Insiders
0.52%
Institutions
91.88%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC7.55%
HHG PLC7.27%
Johnson & Johnson5.26%
Franklin Resources Inc4.89%
Balyasny Asset Management LLC4.48%
Millennium Management LLC4.08%
Baker Bros Advisors LP3.78%
RA Capital Management, LLC3.44%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Contineum Therapeutics, Inc. Class A Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.